Trial · NCT07065591
Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity
NCT07065591, Early phase 1, Recruiting, The University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity. Trials, record NCT07065591. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07065591
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity
- NCT number
- NCT07065591
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 100 participants, estimated
- Lead sponsor
- The University of Hong Kong
- Conditions
- Osteoarthritis (OA) of the Knee
- Interventions
- Metformin, Placebo
- First posted
- 2025-07-15
- Last updated
- 2026-08-18
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain by visual analogue scale | At 0,1.5, 3, 6 and 12 months | Measure the change in pain level through visual analogue scale (VAS) (0-100mm) |
| Secondary | Western Ontario and McMaster Universities Arthritis Index (WOMAC) | At 0,1.5, 3, 6 and 12 months | Western Ontario and McMaster Universities Arthritis Index (WOMAC) consists of 24 items divided into 3 subscales Pain (5 items), Stiffness (2 items)Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total WOMAC score. |
| Secondary | Body weight | At 0,1.5, 3, 6 and 12 months | Body weight (kg - kilogram) will be measured at each visit. |
| Secondary | Knee stiffness | At 0,1.5, 3, 6 and 12 months | It is measured by knee range measurement |
| Secondary | Physical Activity through questionnaire | At 0,1.5, 3, 6 and 12 months | It is measured by the International Physical Activity Questionnaire short version. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). |
| Secondary | Willingness to proceed TKR immediately | At 0,1.5, 3, 6 and 12 months | It is measured as proxy of need of TKR. |
| Secondary | Physical performance of the muscle - walk | At 0,1.5, 3, 6 and 12 months | It is measured by 6-metre walk: time to walk 6 metres without deceleration is taken (average of 2 trials is taken, cut-off \<1.0m/s). |
| Secondary | Physical performance of the muscle - chair stand | At 0,1.5, 3, 6 and 12 months | It is measured by 5-time chair stand test: time to rise from chair 5 times is recorded (cut-off≥12 seconds). |
| Secondary | Physical performance of the muscle - balance | At 0,1.5, 3, 6 and 12 months | It is measured by Short Physical Performance Battery (SPPB, cut-off\<=9). Patients will perform the balance test first, followed by the gait speed test, and finally the chair stand test. Each test will be scored individually, and the total score will be calculated by summing the scores of all three tests. The overall score ranges from 0 to 12, with 12 indicating the best performance. |
| Secondary | Muscle strength - Handgrip strength | At 0,1.5, 3, 6 and 12 months | It is measured by spring-type handgrip dynamometer (JAMAR Hand Dynamometer) with dominant hand in a maximum-effort isometric contraction (cut-off=M: \<28 kg, F: \<18 kg) |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07065591
GET https://conductscience.org/api/trials/v1/NCT07065591/registered?page=2